Neonatal Intensive Care Drug Manual

2. Refractory Hyperinsulinaemic Hypoglycaemia

2. 1 to 5 microgram/ kg/ dose every 6 hours

2. Subcut/IV injection

2. 10 microgram /kg / dose every 6 hours

- Octreotide is a somatostatin analogue - It inhibits release of growth hormone and of various peptides of the gastroenteropancreatic endocrine system (including insulin)

- Common adverse events include flatulence, vomiting, diarrhoea, abdominal distension, hyperglycaemia, hypoglycaemia, hypothyroidism.

- Necrotising enterocolitis has been reported in term neonates administered octreotide.

- Rarely octreotide can cause hepatic dysfunction, bradycardia, steatorrhea

- Monitor blood glucose, thyroid function, liver function, urea and electrolytes, signs and symptoms of necrotising enterocolitis

- Avoid abrupt withdrawal of octreotide to avoid biliary colic and pancreatitis. Infusion can be gradually decreased over 2 to 7 days

- In refractory hyperinsulinaemic hypoglycaemia, tachyphylaxis to treatment may occur within several days

Use Octreotide short acting formulation only

Draw up 125 microgram/kg and make up to 25 mL total volume with 0.9% sodium chloride